Preferred Name |
Dasatinib |
|
Synonyms |
|
|
Definitions |
An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes. |
|
ID |
http://purl.obolibrary.org/obo/NCIT_C38713 |
|
Accepted_Therapeutic_Use_For |
Chronic myeloid leukemia; Philadelphia chromosome-positive acute lymphoblastic leukemia |
|
ALT_DEFINITION |
A drug used to treat certain types of chronic myeloid leukemia and acute lymphoblastic leukemia. BMS-354825 is also being studied in the treatment of certain other blood diseases and types of cancer. BMS-354825 binds to and blocks BCR-ABL and other proteins that help cancer cells grow. It is a type of tyrosine kinase inhibitor. |
|
CAS_Registry |
863127-77-9 |
|
Chemical_Formula |
C22H26ClN7O2S.H2O |
|
code |
C38713 |
|
Contributing_Source |
CTRP FDA |
|
definition |
An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes. |
|
Display_Name |
Dasatinib |
|
FDA_UNII_Code |
RBZ1571X5H |
|
Has_Target |
http://purl.obolibrary.org/obo/NCIT_C26156 http://purl.obolibrary.org/obo/NCIT_C17328 http://purl.obolibrary.org/obo/NCIT_C16325 |
|
in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C173383 http://purl.obolibrary.org/obo/NCIT_C173381 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
Is_Value_For_GDC_Property | ||
label |
Dasatinib |
|
Legacy Concept Name |
BMS-354825 |
|
Maps_To |
Dasatinib |
|
NCI_Drug_Dictionary_ID |
315885 |
|
NSC Number |
732517 |
|
PDQ_Closed_Trial_Search_ID |
315885 |
|
PDQ_Open_Trial_Search_ID |
315885 |
|
Preferred_Name |
Dasatinib |
|
prefixIRI |
NCIT:C38713 |
|
prefLabel |
Dasatinib |
|
Semantic_Type |
Pharmacologic Substance |
|
UMLS_CUI |
C1455147 |
|
subClassOf |